Insider · CIK 0001163556
N Scott Fine
Files at CYTH (Cyclo Therapeutics, Inc.). First filing Apr 24, 2023, latest Apr 24, 2023.
In brief
N Scott Fine files SEC Form 4 as CEO and director at CYTH (Cyclo Therapeutics, Inc.). Since Apr 24, 2023, N Scott Fine has reported 1 open-market buy worth $213k and 0 open-market sells worth $0, the latest filed on Apr 24, 2023.
A track record needs three past buys with six months of prices behind them; N Scott Fine has 0, so none is measured yet.
The newest scored trade: bought $213k of CYTH on Apr 20, 2023, filed Apr 24, 2023, scored 62 (notable).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 62Notable | Cyclo Therapeutics, Inc. | $213k 299,402 shares | +206% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | CYTH Cyclo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +266,354 | $0.00 | $0 | 266,354 | Jun 5, 2024 |
| Oct 20, 2023 | CYTH Cyclo Therapeutics, Inc. | XIn-the-money exercise Common Stock | +299,402 | $0.71 | $213k | 743,804 | Oct 23, 2023 |
| Oct 20, 2023 | CYTH Cyclo Therapeutics, Inc. | XIn-the-money exercise Warrant to Purchase Common Stockderivative | -299,402 | $0.13 | $37k | 0 | Oct 23, 2023 |
| Oct 20, 2023 | CYTH Cyclo Therapeutics, Inc. | POpen-market purchase Warrant to Purchase Common Stockderivative | +329,342 | - | - | 329,342 | Oct 23, 2023 |
| Apr 20, 2023 | CYTH Cyclo Therapeutics, Inc. | POpen-market purchase Common Stock | +299,402 | $0.71 | $213k | 444,402 | Apr 24, 2023 |
| Apr 20, 2023 | CYTH Cyclo Therapeutics, Inc. | POpen-market purchase Warrant to Purchase Common Stockderivative | +299,402 | $0.13 | $37k | 299,402 | Apr 24, 2023 |
| Mar 7, 2023 | CYTH Cyclo Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +98,706 | $0.00 | $0 | 98,706 | Mar 9, 2023 |
Questions about N Scott Fine
Answered from the filings on this page, as of the latest one.
Is N Scott Fine buying or selling?
Not in the last 12 months. N Scott Fine's latest open-market trade on SEC Form 4 was bought $213k of CYTH on Apr 20, 2023.
How did N Scott Fine's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and N Scott Fine has 0.
Where does N Scott Fine file Form 4?
N Scott Fine has filed Form 4 at CYTH (Cyclo Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.